Bond.az White LogoBond.az Black Logo

Mizuho Raises STM Price Target on AI Growth

Mizuho raises STMicroelectronics price target to $68, citing AI growth and new technologies.

Olivia Taylor
ByOlivia Taylor- Senior Editor
|
0

Mizuho raised its price target for STMicroelectronics (STM) shares to $68 from $56, maintaining an Outperform rating. The stock currently trades at $60.96, up 139% over the past year and 174% in the last six months.

The firm cited increasing AI server content reaching $230 million per gigawatt as customers transition to 800-volt architectures. Silicon photonics ramps are expected to accelerate into 2027.

STMicroelectronics indicated AI revenue could exceed $1 billion in 2026. Mizuho based its new target on 30 times its fiscal 2027 EPS estimate, up from approximately 25 times previously. The company trades at a P/E ratio of 375, reflecting elevated growth expectations.

Low Earth orbit satellite applications represent a serviceable addressable market estimated at $2.9 billion by 2030. Electric vehicle applications also remain a key growth driver.

In other recent news, STMicroelectronics reported mixed Q1 2026 earnings. EPS missed at $0.13 vs. $0.17 forecast, but revenue beat at $3.1 billion vs. $3.04 billion. Mizuho, UBS, Craig-Hallum, and Baird all raised price targets.

More News
Today / 12:04
|
952

Raymond James Backs Nutrien Stock on Potash

Raymond James backs Nutrien stock with Outperform rating and $90 target after Indian potash deal. 26% upside, strong financials.

0
Today / 11:03
|
967

Oppenheimer Reiterates Outperform on UroGen Pharma

Oppenheimer reiterates Outperform on UroGen Pharma with $40 target. Strong commercial momentum for Zusduri driven by physician enthusiasm.

0
Today / 11:02
|
510

Guggenheim Upgrades StubHub Stock on Reset

Guggenheim upgrades StubHub stock to Buy with a $12.50 price target, citing reset expectations and growth catalysts like the World Cup.

0
Today / 10:31
|
290

Wolfe Research Initiates CytomX Stock with Outperform

Wolfe Research initiated CytomX Therapeutics (CTMX) with an outperform rating and $3.50 target. Varseta-M shows promise in colorectal cancer.

0
Today / 10:30
|
842

Wolfe Research initiates Mirum with outperform

Wolfe Research starts Mirum Pharmaceuticals with outperform rating and $145 price target, citing strong pipeline potential.

0
Today / 10:14
|
236

Wolfe Research Initiates Oklo with Peerperform

Wolfe Research initiated Oklo Inc. with a Peerperform rating. Learn about the company's targets, finances, and stock performance.

0
Today / 10:13
|
631

Aletheia Capital Reaffirms Circle Stock Rating

Aletheia Capital reaffirms Buy rating on Circle Internet Group amid U.S. stablecoin regulatory advantages. Stock at $111.39.

0
Today / 09:31
|
784

Jefferies Initiates X-Energy Stock with Hold Rating

Jefferies initiates X-Energy stock coverage with a Hold rating and $28 target. Learn about risks and recent performance.

0
Today / 09:11
|
441

UBS Upgrades Jazz Pharma on Ziihera Potential

UBS upgrades Jazz Pharmaceuticals to Buy with a $307 target on Ziihera potential. Bond.az provides detailed analysis and stock insights.

0
Today / 09:10
|
408

UBS Starts X-Energy Stock Coverage with Buy

UBS starts coverage on X-Energy stock with a buy rating and $40 target. The company's reactor model and growth potential are highlighted.

0
Today / 08:55
|
525

Goldman Sachs Upgrades Brambles on Subcontractor Exit

Goldman Sachs upgrades Brambles to Neutral after subcontractor exit. Stock drops 17%, but Bond.az analysis suggests undervaluation with $32.76 Fair Value.

0
Yesterday / 20:21
|
381

RBC Capital hikes Dominion Resources price target

RBC Capital raises Dominion price target to $72 on NextEra deal. Sector Perform rating maintained with 7% arbitrage spread.

0
...